---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-050219"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T02:38:24.561601+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Armata's AP-SA02 shows 100% clinical response in Phase 1b/2a S. aureus bacteremia trial

## Summary
- Primary endpoints met: safety, tolerability, and clinical response in ITT (n=50).
- AP-SA02 + BAT achieved 100% clinical response at TOC for BAT and EOS vs 75% for placebo (p=0.017).
- No treatment-related serious adverse events; two possibly related events (liver enzyme elevation, hypersensitivity).
- At day 12, responder rate 88% AP-SA02 vs 58% placebo (p=0.047); MRSA patients had no relapse.
- Company plans to initiate a pivotal trial as rapidly as possible.

## SEC filing metadata
- accession: 0001104659-25-050219
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465925050219/0001104659-25-050219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465925050219/tm2515395d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-050219
- JSON: https://secwatch.observer/filing/0001104659-25-050219.json
- Plain text: https://secwatch.observer/filing/0001104659-25-050219.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.